Edgewise Therapeutics, Inc. (EWTX) Institutional Ownership

Ownership Summary

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has 194 institutional investors that have filed 13F reports for the period ending December 2025.

• Their combined ownership stood at 115.1% of outstanding shares in December 2025, up from 106.5% in September 2025.
• They increased total shares held in EWTX by 10.7% quarter over quarter, and investors in Edgewise Therapeutics decreased 2.51% from a year ago.
• Of these 194 funds, 114 grew their exposure to Edgewise Therapeutics, 53 cut back, and 27 maintained positions.
• Institutional investors collectively held 121.43Mn shares in Edgewise Therapeutics as of December 2025, up by 11.74Mn shares quarter on quarter, and up 21.25Mn shares year over year.
• As of December 31, 2025, ORBIMED ADVISORS LLC held the largest stake in Edgewise Therapeutics with 15.52Mn shares, accounting for 14.71% of total shares outstanding.
• Leading buyers of Edgewise Therapeutics shares for the quarter ending December 2025 were Janus Henderson Group Plc (7.26Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.79Mn), Paradigm Biocapital Advisors LP (823.83K), ALLIANCEBERNSTEIN L.P. (686.0K), VANGUARD PORTFOLIO MANAGEMENT LLC (557.26K).
• The biggest sellers of Edgewise Therapeutics for the quarter ending December 2025 included BRAIDWELL LP (2.86Mn), Goldman Sachs Group Inc (806.92K), UBS Group AG (805.95K), Morgan Stanley (664.85K), First Light Asset Management, LLC (571.86K).
• According to Business Quant data, leading holders of EWTX for December 2025 are ORBIMED ADVISORS LLC (15.52Mn), Janus Henderson Group Plc (11.83Mn), RA CAPITAL MANAGEMENT, L.P. (10.43Mn), Paradigm Biocapital Advisors LP (7.37Mn), BAKER BROS. ADVISORS LP (6.58Mn), BlackRock, Inc. (6.47Mn), Novo Holdings A/S (5.35Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (4.48Mn), Siren, L.L.C. (4.43Mn), PERCEPTIVE ADVISORS LLC (4.42Mn).